Pulmatrix Investor Relations Material
Latest events
M&A Announcement
Pulmatrix
Q1 2025
5 Sep, 2025
Q2 2025
5 Aug, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pulmatrix Inc
Access all reports
Pulmatrix Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases. The company utilizes its proprietary iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted) technology to formulate dry powder drugs for efficient delivery to the lungs. Pulmatrix's pipeline includes treatments for conditions such as chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and other respiratory disorders. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Pulmatrix Inc
M&A Announcement
Pulmatrix Inc
M&A Announcement
Pulmatrix Inc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
PULM
Country
🇺🇸 United States